More Talk, Less Work: US FDA Outlines Expectations For Combo Products Discussions
Executive Summary
A new FDA draft guidance says manufacturers of combination products should first review existing combination product guidances and submit questions before asking for a combination product agreement meeting with regulators to get clarification. The guidance outlines what is expected of both sides in such meetings.
You may also be interested in...
Combination Product Sponsors Should Consider Traditional Pathways Before Asking For Meeting, US FDA Says
In a final guidance from the US agency, regulators say most combination product questions are best resolved through traditional pathways and noted that initiating a so-called combination product agreement meeting may be unproductive.
FDA To Combo Product Sponsors: Consider Traditional Pathways Before Asking For Meeting
In a final guidance from the US agency, regulators say most combination product questions are best resolved through traditional pathways and noted that initiating a so-called combination product agreement meeting may be unproductive.
FDA Draft Guidance Urges Consistency, Plain Language In Combo Product Instructions
A new draft guidance document from the US agency offers nuts-and-bolts guidance on formatting Instructions for Use (IFUs) for drug-device and biologic-device combination product applications.